Impax Must Pay For GSK Wellbutrin Settlement, Teva Says
By Dan Packel ( August 31, 2017, 5:46 PM EDT) -- Teva Pharmaceuticals said that misrepresentations from drugmaker Impax Laboratories about the bioequivalence of a now-discontinued generic version of antidepressant Wellbutrin left it exposed to hundreds of millions of dollars in damages to Wellbutrin manufacturer GlaxoSmithKline, in a complaint filed in Pennsylvania state court Wednesday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.